Evaluation of Systemic Autoimmune Rheumatic Autoantibodies in post-COVID-19 Patients and Their Impact on Clinical Outcomes: A Retrospective-Cohort Study COVID-19 Geçiren Hastalarda Sistemik Otoimmün Romatizmal Otoantikorların Değerlendirilmesi ve Bunların Klinik Sonuçlar Üzerindeki Etkisi: Retrospektif Kohort Bir Çalışma
Turkiye Klinikleri Journal of Medical Sciences, cilt.45, sa.2, ss.66-76, 2025 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 45 Sayı: 2
- Basım Tarihi: 2025
- Doi Numarası: 10.5336/medsci.2024-105195
- Dergi Adı: Turkiye Klinikleri Journal of Medical Sciences
- Derginin Tarandığı İndeksler: Scopus, Central & Eastern European Academic Source (CEEAS), CINAHL, EMBASE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.66-76
- Anahtar Kelimeler: autoantibodies, autoimmune diseases, Coronavirus disease-2019, musculoskeletal abnormality, post-acute-coronavirus disease-2019 syndrome
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The role of systemic autoimmunity in post-coronavirus disease-2019 (COVID-19) patients from real-world data is still un-known. The aim of our study was to evaluate the presence of rheumatic and antiphospholipid antibodies in post-COVID-19 patients and examine their frequencies and the clinical outcomes. Material and Methods: The data of 393 people who had COVID-19 and were followed up in our outpatient clinic were retrospectively analyzed. In our descriptive study, clinical and biochemical parameters as well as the presence of antinuclear antibodies, antiphospholipid antibodies, romatoid factor and immunoglobulin G cyclic citrullinated peptide 3rd generation were evaluated in all patients. Results: One hundred fifty nine of 393 (40.5%) patients had at least one autoimmune reactivity. 31 patients with 1 or more autoantibodies positivity and/or ac-companying musculoskeletal symptoms after COVID-19 were referred to the rheumatology outpatient clinic. Autoimmune disease was diagnosed in 9 of these patients. The distribution of autoimmune disease diagnoses is as follows; systemic lupus erythematosus (SLE) or SLE-like syndrome was diagnosed in 3 patients, mixed connective tissue disease in 3 patients, Sjögren’s syndrome in 2 patients and scleroderma in 1 patient. Conclusion: Although it is not possible to establish a cause-and-effect relationship due to the lack of a control group in the design of our study and the lack of serologic laboratory test results before COVID-19 in patients diagnosed with autoimmune diseases, we think it may be important that autoantibodies and acute phase reactants other than ANA and CCP were found to be higher in hospitalized patients and that various systemic autoimmune reactivities were detected in 40% of post-COVID-19 patients.